Efficacy and safety of epoetin alfa in critically ill patients - Wikidata - wikimedia - TriplyDB

Efficacy and safety of epoetin alfa in critically ill patients

Efficacy and safety of epoetin alfa in critically ill patients

http://www.wikidata.org/entity/Q28246281

about

Safety of off-label erythropoiesis-stimulating agents for critically ill patients Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response?Anemia management after acute brain injury Anemia and blood transfusions in critically ill patients Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials The pleiotropic effects of erythropoietin in infection and inflammation Early detection of pneumonia as a risk factor for mortality in burn patients in Menoufiya University Hospitals, Egypt Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk-benefit The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition Relationship between Hemoglobin Levels Corrected by Interdialytic Weight Gain and Mortality in Japanese Hemodialysis Patients: Miyazaki Dialysis Cohort Study Blood transfusion and infection after cardiac surgery Higher doses of erythropoietin-stimulating agents and hyporesponsiveness to their effects are associated with increased mortality among prevalent hemodialysis patients.The effect of erythropoietin on exercise capacity, left ventricular remodeling, pressure-volume relationships, and quality of life in older patients with anemia and heart failure with preserved ejection fraction.What's New in Traumatic Brain Injury: Update on Tracking, Monitoring and Treatment The prevalence of anemia and its association with 90-day mortality in hospitalized community-acquired pneumonia Oxidative stress: Biomarkers and novel therapeutic pathways.Angiogenesis, neurogenesis and brain recovery of function following injury Anemia in critical illness: insights into etiology, consequences, and management Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine Toward an integrated research agenda for critical illness in aging High dose erythropoietin increases brain tissue oxygen tension in severe vasospasm after subarachnoid hemorrhage Major bleeding after percutaneous coronary intervention and risk of subsequent mortality: a systematic review and meta-analysis Hepatocellular heme oxygenase-1: a potential mechanism of erythropoietin-mediated protection after liver ischemia-reperfusion injury.Postoperative high-dose intravenous iron sucrose with low dose erythropoietin therapy after total hip replacement.Recommendations for the transfusion management of patients in the peri-operative period. I. The pre-operative period Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-κB-inducible immune pathways Spanish Consensus Statement on alternatives to allogeneic blood transfusion: the 2013 update of the "Seville Document".Transfusion protocol in trauma.Erythropoietin in traumatic brain injury: study protocol for a randomised controlled trial ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.Discovery of a master regulator of injury and healing: tipping the outcome from damage toward repair.Red blood cell transfusion in the critically ill patient.Erythropoietin in the intensive care unit: beyond treatment of anemia.The prevention of acute kidney injury an in-depth narrative review: Part 2: Drugs in the prevention of acute kidney injury.Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes.A Distinct Region in Erythropoietin that Induces Immuno/Inflammatory Modulation and Tissue Protection.ESA Hyporesponsiveness Is Associated with Adverse Events in Maintenance Hemodialysis (MHD) Patients, But Not with Iron Storage Guilty molecules, guilty minds? The conflicting roles of the innate immune response to traumatic brain injury An Epidemiological Study of Anemia and Renal Dysfunction in Patients Admitted to ICUs across the United States.

P2860

Q24200811-DD1FEDFE-B864-41E8-82D4-A5F8631EFE93 Q24240202-ADAABB5C-5E28-419E-81AD-1D5CEDCB89AF Q24651385-38FF3AEE-4C72-4BAB-8FBF-0FDA012ABC46 Q26745655-2BC1F50E-1630-44B0-A41C-9B9D6F2AE20D Q26822895-442FA49B-3E35-4022-9BA6-A032F0FC40E0 Q26829377-22BF2173-0C84-4D29-86C9-B88657F6C617 Q26864149-E7EB85BF-C7E2-4E18-B288-12A32EB9DA56 Q26999305-628A0A93-12FE-4467-BD99-4A9DEE6E1929 Q26999850-5A921AD6-4E59-4949-806F-4FE6FB08E6F2 Q27339343-FA453994-41AF-4D6E-9159-501C1C57692E Q28468446-6D24DBCE-D6E0-4E41-8244-8D0109F37781 Q30412708-C1C18D92-F467-43F1-B1C7-047C278BCA8E Q30456721-7C0F67EF-DB55-494B-A737-59502509BF4D Q30475623-F1BF2F0A-F807-48B8-A179-E43B34A98D19 Q30959630-84CFC2D9-3352-4EE8-9728-056F70E91BD9 Q33541326-F1066D48-4D32-4057-91D2-ACCA77A84CB6 Q33682262-E37E72FE-CF0E-4260-A91B-706E75F0ECC3 Q33718009-A1760F78-B359-4F29-8E41-D4A5F7CAFA00 Q33738712-8AEE53F5-25E4-4358-A065-D6F2157A521A Q33974292-7CC1FB60-E218-4DE9-8DF5-28AA1884AE8B Q34268968-EC888B08-A74C-4B05-863E-6E2B364938F3 Q34294255-B4EB2DB5-0271-4BBA-B402-3630F1246B91 Q34333274-BB15B67F-8610-4CE6-A258-4AB486350556 Q34353139-EF93AD88-5F4F-44BC-BC1E-AAED7513A5B9 Q34385089-FD455CBD-FB98-447A-BE0D-8EDD62428587 Q34492729-15E56611-1AF8-4DFF-956A-323274198915 Q34544348-9E193CBF-4694-4678-A071-7425AF62E817 Q34654443-54ECD138-1C6D-4AFF-841F-6AE7753F4AA1 Q34991206-C26F2161-81A3-43E3-A118-313F406D4C0E Q35079125-B324E6C1-3E76-4103-9CF2-4A3B7F082CAF Q35192848-ABC0303F-50BB-4C54-A7E7-F22944E1FCEF Q35219021-D83A2F9C-9F6F-40F4-A7D5-1DB1A953EA7E Q35520728-FB451C95-BB56-4EC5-8E55-764F562B68E9 Q35574024-18FA3C06-9D06-42E5-9902-055C9A1FAC97 Q35574190-F00867B7-AEA3-4B0F-A049-E24B222B4F0C Q35642998-B9BE343E-0A61-4990-A650-B78CDF0A978F Q35745446-EFD59B43-7B05-496C-827F-43E0E1B1F0B1 Q35942721-C9A58443-D046-45FE-A133-CC7912802CBE Q36026673-C62CCCEA-ACD3-4941-A56C-FECBE6CCE5EB Q36180492-66FA1D5B-41FB-4B87-B0F7-D9770DD33DF0

P2860

Efficacy and safety of epoetin alfa in critically ill patients

http://www.wikidata.org/entity/Q28246281

description

2007 nî lūn-bûn

@nan

2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Efficacy and safety of epoetin alfa in critically ill patients

@ast

Efficacy and safety of epoetin alfa in critically ill patients

@en

Efficacy and safety of epoetin alfa in critically ill patients

@nl

type

label

Efficacy and safety of epoetin alfa in critically ill patients

@ast

Efficacy and safety of epoetin alfa in critically ill patients

@en

Efficacy and safety of epoetin alfa in critically ill patients

@nl

prefLabel

Efficacy and safety of epoetin alfa in critically ill patients

@ast

Efficacy and safety of epoetin alfa in critically ill patients

@en

Efficacy and safety of epoetin alfa in critically ill patients

@nl

P1433

Q28246281-B477E0CA-5FF8-4971-ADB3-61F46E0D6D40

P1476

Q28246281-A4EA4586-2043-4B3C-A437-18660D04ECCD

P2093

Q28246281-35C051B5-7B7A-4129-96D8-41F7D66EC70F

Q28246281-3883C5AB-99A1-4AE8-A946-E41D408D9690

Q28246281-3C61AD2B-98EF-426E-9391-9555CAE12BD2

Q28246281-3C8156D1-F184-43F9-B939-D4DB8B04749D

Q28246281-4DE93129-5D35-42EE-AD30-924850F41EC2

Q28246281-6427C478-17E0-4CB3-9511-5460762C74F2

Q28246281-71035D4C-4CE1-49AE-AD35-A858B3832E97

Q28246281-747B5390-831F-4F8C-A035-25DB9AA378A1

Q28246281-7765A2F3-B3B0-4629-9D11-D8CABA5D3143

Q28246281-AC7A6CBD-E60B-439E-AB4F-B4A4E9A02D1B

P304

Q28246281-745F526D-1619-4FCF-B618-D4B577C8BBDF

P31

Q28246281-A7349258-BA6D-480D-B889-F282ACC58FBC

P3181

Q28246281-5EF5442B-C999-4BB1-A697-19D2F5DD8981

P356

Q28246281-2F8FD8D9-1D37-4C5D-A9EC-762C4D3BEB4E

P407

Q28246281-60234936-181E-4D35-9EC4-0480046F042E

P433

Q28246281-0E615E18-D188-41A0-AED2-E58AADB1BFE5

P478

Q28246281-E3620883-1E65-47DF-B27B-98BB880351C8

P577

Q28246281-4DE776DF-B9DF-4C27-9AA1-ECD40273806D

P698

Q28246281-AB0D87D4-7669-48EF-A528-F524CE696AC2

P921

Q28246281-3EE51DA6-85AE-495A-8411-06C021321D19

P3181

P356

P1433

The New England Journal of Medicine

P1476

Efficacy and safety of epoetin alfa in critically ill patients

@en

P2093

Addison May

http://www.w3.org/2001/XMLSchema#string

Andrew Gettinger

http://www.w3.org/2001/XMLSchema#string

Howard L Corwin

http://www.w3.org/2001/XMLSchema#string

Mark A Klausner

http://www.w3.org/2001/XMLSchema#string

Michael J Corwin

http://www.w3.org/2001/XMLSchema#string

Paul Burton

http://www.w3.org/2001/XMLSchema#string

Peter J Bowers

http://www.w3.org/2001/XMLSchema#string

Robert An

http://www.w3.org/2001/XMLSchema#string

Ronald G Pearl

http://www.w3.org/2001/XMLSchema#string

Stephen Heard

http://www.w3.org/2001/XMLSchema#string

P304

965-76

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

685459

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA071533

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

357

http://www.w3.org/2001/XMLSchema#string

P577

2007-09-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17804841

http://www.w3.org/2001/XMLSchema#string

P921